SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-089263
Filing Date
2024-08-01
Accepted
2024-08-01 16:07:27
Documents
13
Period of Report
2024-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20240801.htm   iXBRL 8-K 43314
2 EX-99.1 rare-ex99_1.htm EX-99.1 287337
3 GRAPHIC img45776771_0.jpg GRAPHIC 7330
  Complete submission text file 0000950170-24-089263.txt   469997

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rare-20240801.xsd EX-101.SCH 23897
15 EXTRACTED XBRL INSTANCE DOCUMENT rare-20240801_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 241166640
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)